Seminars in Oncology
Volume 31, Issue 1 , Pages 68-82, February 2004

Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies☆

  • Wolfgang A Bethge

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    • ,
  • Brenda M Sandmaier

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N D1-100, Seattle, WA 98109-1024, USA
    • Department of Medicine, University of Washington, Seattle, WA, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported in part by Grants No. HL36444, CA78902, and CA15704 awarded by the National Institutes of Health, Department of Health and Human Services, Bethesda, MD, and by a grant from the Gabrielle Rich Leukemia Foundation. W.A.B. was supported by a fellowship from Deutsche Krebshilfe, Dr. Mildred-Scheel-Stiftung für Krebsforschung.

PII: S0093-7754(03)00566-9

doi:10.1053/j.seminoncol.2003.11.004

Seminars in Oncology
Volume 31, Issue 1 , Pages 68-82, February 2004

Article Tools

* Image Usage & Resolution